Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Dispenzieri

Showing results (141-150 of 154) with videos related to

Pageof 16
Sort By:
Blood Cancer Journal|December 8, 2021
"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experienceI Vaxman, J Abeykoon, A Dispenzieri, et al.
Journal of Internal Medicine|April 26, 2017
Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosisE Muchtar, D S Dean, A Dispenzieri, et al.
Leukemia|November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaA Dispenzieri, G A Wiseman, M Q Lacy, et al.
Blood Cancer Journal|February 18, 2017
Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myelomaN Tandon, S V Rajkumar, B LaPlant, et al.
Leukemia|December 22, 2017
Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over timeS K Kumar, A Dispenzieri, R Fraser, et al.
Leukemia|September 19, 2017
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chainsS Sidana, N Tandon, A Dispenzieri, et al.
Leukemia|November 2, 2011
Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant ResearchA Mahindra, M E Kalaycio, J Vela-Ojeda, et al.
Leukemia|June 29, 2017
Natural history of t(11;14) multiple myelomaA Lakshman, M Alhaj Moustafa, S V Rajkumar, et al.
Bone Marrow Transplantation|August 4, 2009
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinomaM R Litzow, P P Peethambaram, S L Safgren, et al.
Leukemia|September 2, 2017
Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trialS Ailawadhi, J R Mikhael, B R LaPlant, et al.
Pageof 16

Showing results (141-150 of 154) with videos related to

Sort By:
Pageof 16
Blood Cancer Journal|December 8, 2021
"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experienceI Vaxman, J Abeykoon, A Dispenzieri, et al.
Journal of Internal Medicine|April 26, 2017
Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosisE Muchtar, D S Dean, A Dispenzieri, et al.
Leukemia|November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaA Dispenzieri, G A Wiseman, M Q Lacy, et al.
Blood Cancer Journal|February 18, 2017
Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myelomaN Tandon, S V Rajkumar, B LaPlant, et al.
Leukemia|December 22, 2017
Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over timeS K Kumar, A Dispenzieri, R Fraser, et al.
Leukemia|September 19, 2017
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chainsS Sidana, N Tandon, A Dispenzieri, et al.
Leukemia|November 2, 2011
Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant ResearchA Mahindra, M E Kalaycio, J Vela-Ojeda, et al.
Leukemia|June 29, 2017
Natural history of t(11;14) multiple myelomaA Lakshman, M Alhaj Moustafa, S V Rajkumar, et al.
Bone Marrow Transplantation|August 4, 2009
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinomaM R Litzow, P P Peethambaram, S L Safgren, et al.
Leukemia|September 2, 2017
Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trialS Ailawadhi, J R Mikhael, B R LaPlant, et al.
Pageof 16